A Randomized, Single-blind, Controlled Clinical Study of Cardiomyopeptidin on Improving Ischemia-reperfusion Injury in Patients With Acute ST-segment Elevation Myocardial Infarction After Primary PCI

NCT06155110 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

160

Enrollment

OTHER

Sponsor class

Conditions

Cardiovascular Diseases

Interventions

DRUG: cardiomyopeptidin

Sponsor

Chinese PLA General Hospital

Collaborators

[object Object]